Category

2024

[article_filters]

Posters, Scientific Publications

MaaT013 Pooled Fecal Microbiotherapy Improves Gastrointestinal Physiology And Controls Inflammation Which Delays GvHD In A Proof-Of-Concept Humanized Mouse Study

November 12, 2025

Posters, Scientific Publications

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice

November 5, 2025

Posters, Scientific Publications

MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity

April 4, 2025

Replay: KOL insights and MaaT013 Data from ASH 2024 Meeting

December 18, 2024

December 10, 2024: MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH 2024 Annual Meeting

December 10, 2024

Posters, Scientific Publications

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe

December 9, 2024

December 5, 2024: MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded Access for MaaT013 in Acute Graft-versus-Host Disease

December 5, 2024

35th International Symposium on ALS/MND

December 3, 2024

ASH Annual Meeting and Exposition

December 3, 2024

November 26, 2024: MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral Sclerosis (ALS)

November 26, 2024

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact

We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.

COMPANY

Ressources

Contact